UL Solutions Inc. (NYSE: ULS) announced that it will acquire Eurofins Scientific SE’s Electrical & Electronics (E&E) business, which includes the MET Labs certification mark, in a definitive agreement valued at an enterprise value of approximately €575 million (about $670 million). The deal is expected to close in the fourth quarter of 2026 and will add roughly 1,300 staff worldwide to UL’s operations.
The acquisition expands UL’s global laboratory footprint, particularly in EMEA and Asia‑Pacific, and strengthens its testing, inspection and certification services for electrical safety and connected products. By integrating MET Labs’ capabilities, UL will accelerate its shift toward higher‑margin industrial testing services and support its portfolio realignment toward testing, inspection and certification (TIC) and risk‑and‑compliance software.
Funding for the transaction will come from UL’s existing cash reserves, proceeds from the sale of its Employee Health and Safety software business (closed April 1 2026), and available capacity on its revolving credit facility. Approximately 30 % of the purchase price will be financed with the software‑business sale proceeds.
Management highlighted the strategic fit of the transaction. President and CEO Jennifer Scanlon said, "This transaction fits our ambition to be the acquirer of choice." She added that the deal positions UL to capture growing demand for electrical safety certification driven by electrification and data‑center megatrends.
Eurofins Scientific’s divestment aligns with its strategy to focus on core sectors such as food, environmental, and pharmaceutical testing. The sale is expected to provide Eurofins with additional capital for debt reduction and investment in its core businesses.
UL Solutions expects the acquisition to be accretive to Adjusted Diluted Earnings Per Share in the first full calendar year after closing, and it should not materially impact the company’s 2026 full‑year outlook, which includes mid‑single‑digit constant‑currency organic revenue growth and an Adjusted EBITDA margin of 26.5% to 27.0%.
The transaction is subject to customary regulatory approvals and is anticipated to close in Q4 2026.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.